Alice Hosking

Alice Hosking

Auto-generated profile, based on publicly available information

Alice Hosking

The University of Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
AHAlice Hosking
Alice Hosking
AHAdrianus A.L.J. Hommel
Adrianus A.L.J. Hommel
SLStefan Lorenzl
Stefan Lorenzl
MCMiguel Coelho
Miguel Coelho
JFJoaquim J. Ferreira
Joaquim J. Ferreira
ASAnette-Eleonore Schrag
Anette-Eleonore Schrag

6 October 2016 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
AHAlice Hosking
Alice Hosking
MKMarinos Koulouroudias
Marinos Koulouroudias
FZFilip Zemrak
Filip Zemrak
JMJames C. Moon
James C. Moon
ARAlexia Rossi
Alexia Rossi
SPSteffen Petersen
Steffen Petersen
Adenosine can induce splenic vasoconstriction (splenic switch-off, SSO). In this study, we aim to evaluate the utility of identifying a lack of SSO for detecting false-negative adenosine stress perfusion cardiac magnetic resonance (CMR) scans. We visually analysed 492 adenosine stress perfusion CMR scans reported as negative in a cohort of patients with no previous history of coronary artery disease. A lack of SSO was identified in 11%. We quantified the phenomenon by drawing regions of interest on the spleen and comparing intensity between stress and rest scans, the spleen intensity ratio (SIR). Inter-rater agreement for qualitative determination of SSO was κ = 0.81 and inter-class correlation for quantitative determination of SSO was 0.94. The optimal threshold for SIR as an indicator of SSO was 0.40 (sensitivity = 82.5%, specificity = 92.3%, AUC = 0.91). 23 065 CMR scans and 9926 invasive coronary angiogram reports were retrospectively examined to identify patients with negative CMR scans who required coronary intervention in the subsequent 12 months (false negatives). We compared these scans with true positives who had positive adenosine stress perfusion CMR scans followed by coronary intervention. The rate of lack of SSO was 20.7% in the false-negative group versus 13.1% in true positives (P = 0.37). The lack of SSO is prevalent, easily measureable, and has potential to improve on haemodynamic criteria as a marker of adenosine understress in CMR perfusion scans.

1 April 2026 in Stroke
Verified
Journal Article
Open access
AHAlice Hosking
Alice Hosking
NSNeshika Samarasekera
Neshika Samarasekera
TMTom J. Moullaali
Tom J. Moullaali
WWWilliam N. Whiteley
William N. Whiteley
VPVega Pratiwi Putri
Vega Pratiwi Putri
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
Most people with spontaneous intracerebral hemorrhage (ICH) have hypertension, which is the strongest modifiable predisposing (risk) factor. However, multiple long-term medical conditions and other known predisposing factors for ICH usually coexist with hypertension, indicating that the causal pathway is multifactorial, and the term hypertensive ICH is oversimplistic. In this review, we integrate the highest quality evidence and our clinical experience in a framework to attribute multiple predisposing factors, underlying pathologies, and precipitating factors as the cause of ICH. In clinical practice, this framework supports physicians to take a holistic approach to treatment and prevention of ICH. In research, this framework shows how existing classification systems for the cause of ICH include underlying macrovascular, microvascular, and other structural pathologies but few predisposing or precipitating factors. Furthermore, this framework can inform the development of a more holistic classification system and expose knowledge gaps, including how predisposing factors lead to underlying pathologies and why only some people with these pathologies experience ICH.

13 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MIMatthew H Iveson
Matthew H Iveson
MMMome Mukherjee
Mome Mukherjee
EDEmma M Davidson
Emma M Davidson
HZHuayu Zhang
Huayu Zhang
LSLaura Sherlock
Laura Sherlock
WWWilliam N Whiteley
William N Whiteley
Importance Understanding the relevance of covert cerebrovascular disease (CCD) for later health will allow clinicians to more effectively monitor and target interventions. Objective To examine the association between clinically reported CCD, measured using natural language processing (NLP), and subsequent disease risk. Design, Setting and Participants We conducted a retrospective e-cohort study using linked health record data. From all people with clinical brain imaging in Scotland from 2010 to 2018, we selected people with no prior hospitalisation for neurological disease. The data were analysed from March 2024 to June 2025. Exposure Four phenotypes were identified with NLP of imaging reports: white matter hypoattenuation or hyperintensities (WMH), lacunes, cortical infarcts and cerebral atrophy. Main outcomes and measures Hazard ratios (aHR) for stroke, dementia, and Parkinson’s disease (conditions previously associated with CCD), epilepsy (a brain-based control condition) and colorectal cancer (a non-brain control condition), adjusted for age, sex, deprivation, region, scan modality, and pre-scan healthcare, were calculated for each phenotype. Results From 395,273 people with brain imaging and no history of neurological disease, 145,978 (37%) had ≥1 phenotype. For each phenotype, the aHR of any stroke was: WMH 1.4 (95%CI: 1.3–1.4), lacunes 1.6 (1.5–1.6), cortical infarct 1.7 (1.6–1.8), and cerebral atrophy 1.1 (1.0–1.1). The aHR of any dementia was: WMH, 1.3 (1.3–1.3), lacunes, 1.0 (0.9–1.0), cortical infarct 1.1 (1.0–1.1) and cerebral atrophy 1.7 (1.7–1.7). The aHR of Parkinson’s disease was, in people with a report of: WMH 1.1 (1.0–1.2), lacunes 1.1 (0.9–1.2), cortical infarct 0.7 (0.6–0.9) and cerebral atrophy 1.4 (1.3–1.5). The aHRs between CCD phenotypes and epilepsy and colorectal cancer overlapped the null. Conclusions and Relevance NLP identified CCD and atrophy phenotypes from routine clinical image reports, and these had important associations with future stroke, dementia and Parkinson’s disease. Prevention of neurological disease in people with CCD should be a priority for healthcare providers and policymakers. Question Are measures of Covert Cerebrovascular Disease (CCD) associated with the risk of subsequent disease (stroke, dementia, Parkinson’s disease, epilepsy, and colorectal cancer)? Findings This study used a validated NLP algorithm to identify CCD (white matter hypoattenuation/hyperintensities, lacunes, cortical infarcts) and cerebral atrophy from both MRI and computed tomography (CT) imaging reports generated during routine healthcare in >395K people in Scotland. In adjusted models, we demonstrate higher risk of dementia (particularly Alzheimer’s disease) in people with atrophy, and higher risk of stroke in people with cortical infarcts. However, associations with an age-associated control outcome (colorectal cancer) were neutral, supporting a causal relationship. It also highlights differential associations between cerebral atrophy and dementia and cortical infarcts and stroke risk. Meaning CCD or atrophy on brain imaging reports in routine clinical practice is associated with a higher risk of stroke or dementia. Evidence is needed to support treatment strategies to reduce this risk. NLP can identify these important, otherwise uncoded, disease phenotypes, allowing research at scale into imaging-based biomarkers of dementia and stroke.

16 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
AHAlice Hosking
Alice Hosking
JSJacqueline Stephen
Jacqueline Stephen
JDJonathan Drever
Jonathan Drever
WWWilliam N. Whiteley
William N. Whiteley
CSCathie L.M. Sudlow
Cathie L.M. Sudlow
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
Background Healthcare systems data (HCSD) could improve the efficiency of clinical trials, but their accuracy and validity are uncertain. Our objective was to assess the accuracy of HCSD as the sole method of outcome detection in the REstart or STop Antithrombotics Randomised Trial (RESTART; ISRCTN71907627) compared with adjudicated questionnaire follow-up; and compare estimates of treatment effect. Methods RESTART was a prospective, open, assessor-blind, parallel-group randomized controlled trial (RCT) of antiplatelet therapy after intracerebral haemorrhage (ICH) in the UK. We included 496 (92%) of 537 RESTART participants, who were resident in England or Scotland at randomization. Computerized randomization incorporating minimization allocated participants (1:1) to start or avoid antiplatelet therapy. RESTART used annual questionnaires to detect its primary outcome (recurrent ICH) and secondary outcome (a composite of haemorrhagic or ischemic major adverse cardiovascular events [MACE]) over a median of 2.0 years; an independent adjudication committee verified outcomes using medical records and brain imaging. We obtained ICD10-coded HCSD on hospital admissions and deaths in England and Scotland to identify primary and secondary outcomes. We compared HCSD with a reference standard of adjudicated outcomes. We estimated the effects of antiplatelet therapy using HCSD alone in a Cox proportional hazards model adjusted for minimization variables. Results In the original RESTART trial, 31 people experienced a primary outcome event. HCSD had sensitivity of 84% (95% CI 66% to 95%) and positive predictive value of 68% (51% to 82%) for recurrent ICH. HCSD estimated an effect of antiplatelet therapy (adjusted hazard ratio [aHR] 0.51, 95% CI 0.27 to 0.98; p=0.044) that was almost identical to adjudicated outcomes (aHR 0.51, 95% CI 0.25 to 1.03; p=0.060). HCSD had sensitivity of 84% (76% to 91%) and positive predictive value of 78% (69% to 85%) for MACE, on which HCSD estimated an effect of antiplatelet therapy (aHR 0.81, 95% CI 0.56 to 1.16; p=0.247) that was similar to adjudicated outcomes (aHR 0.65, 95% CI 0.44 to 0.95; p=0.025). Conclusions In a RCT of antiplatelet therapy for people with ICH, HCSD was reasonably accurate and provided similar estimates of treatment effect compared with adjudicated outcomes. Trial registration: RESTART; ISRCTN71907627

6 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ABAnuka Boldbaatar
Anuka Boldbaatar
TMTom J Moullaali
Tom J Moullaali
AMAllan MacRaild
Allan MacRaild
SRSarah Risbridger
Sarah Risbridger
AHAlice Hosking
Alice Hosking
NSNeshika Samarasekera
Neshika Samarasekera
Background: Platform trials are an efficient trial design which enable testing of multiple interventions simultaneously. They could advance knowledge of treatments for intracerebral haemorrhage (ICH). We aimed to investigate the views of clinicians involved in stroke research on recruitment to a future platform trial for ICH. Methods: Between April and July 2025, we conducted a UK-wide online survey of clinicians actively involved in stroke research using convenience sampling through professional organisations. Participants considered factors related to the consent process and research environment and could provide optional free text responses about additional barriers or facilitators to recruitment. We used descriptive statistics for quantitative data and content analysis for qualitative data. Results: Among 73 respondents, 46 (63%) were female, 36 (50%) were stroke physicians, 24 (34%) nurses, 6 (8%) allied health professionals, and 7 (10%) were in other roles. 36 (49%) had >20 years’ clinical experience, 45 (61%) reported spending <10% of their role in research. 66 (91%) thought that a platform trial would be a good option for testing interventions for patients with stroke due to ICH. Across 11 modifiable factors, clinicians most frequently rated perceived importance of the research question as a facilitator of recruitment (94%), while clinician preference for specific treatments was most frequently rated as a barrier (48%). Two themes emerged from free text responses: study design and infrastructure. Regarding study design respondents perceived consent procedures (n=9), study materials (n=8), study procedures (n=8), eligibility assessment (n=6), the research question (n=3) and randomization (n=3) as important for a future platform trial. Regarding infrastructure, emergent factors were staffing (n=17), local research culture and capacity (n=9), research governance and delivery (n=6), and training (n=6). Conclusion: The overwhelming majority of respondents from the UK clinical stroke community supported a platform trial for ICH, although the influence of survey responder bias is unknown.